期刊
CANCER CELL
卷 35, 期 2, 页码 191-+出版社
CELL PRESS
DOI: 10.1016/j.ccell.2018.12.012
关键词
-
资金
- National Natural Science Foundation of China [8153000450, 81871197, 81430032, U1601222]
- Leading Talents of Guangdong Province Program [00201516]
- National High-Tech R&D Program (863 Program) [2015AA020310]
- Development and Reform Commission of Shenzhen Municipality [S2016004730009]
- Sanming Project of Medicine in Shenzhen [SZSM201602102]
- South Wisdom Valley Innovative Research Team Program [(2014) 365]
- California Institute for Regenerative Medicine [TR1-01277]
- Major Basic Research Developmental Project of the Natural Science Foundation of Guangdong Province
The tumor suppressor p53 is somatically mutated in half of all human cancers. Paradoxically, the wild-type p53 (WTp53) is often retained in certain human cancers, such as hepatocarcinoma (HCC). We discovered a physiological and oncogenic role of WTp53 in suppressing pyruvate-driven oxidative phosphorylation by inducing PUMA. PUMA inhibits mitochondrial pyruvate uptake by disrupting the oligomerization and function of mitochondrial pyruvate carrier (MPC) through PUMA-MPC interaction, which depends on I kappa B kinase-mediated phosphorylation of PUMA at Ser96/106. High expression levels of PUMA are correlated with decreased mitochondrial pyruvate uptake and increased glycolysis in HCCs and poor prognosis of HCC patients. These findings are instrumental for cancer drug discovery aiming at activating WTp53 or restoring WTp53 activity to p53 mutants.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据